Vogenx Inc (NASDAQ:VOGX) Shares Shorted: Short Interest Up 93.6% in October

Vogenx Inc (NASDAQ:VOGX) was the target of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 74,122 shares, an increase of 93.6% from the October 15th total of 38,289 shares. Currently, 0.5% of the company’s shares are sold short. Based on an average daily volume of 80,725 shares, the short-interest ratio is presently 0.9 days.

Vogenx Stock Performance

Vogenx stock traded down $2.48 during trading hours on Friday, hitting $16.67. The company had a trading volume of 94,312 shares, compared to its average volume of 98,963. The company has a market cap of $247.55 million and a price-to-earnings ratio of -79.38. The business’s 50-day simple moving average is $22.03. Vogenx has a 1 year low of $12.95 and a 1 year high of $38.41.

Vogenx (NASDAQ:VOGX) last issued its earnings results on Friday, November 6th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. Research analysts forecast that Vogenx will post -0.61 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. WBB Securities began coverage on Vogenx in a research note on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 target price on the stock. Wall Street Zen lowered Vogenx from a “hold” rating to a “sell” rating in a research note on Saturday. JonesTrading assumed coverage on Vogenx in a report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price objective for the company. Zacks Research upgraded Vogenx to a “hold” rating in a report on Monday, September 28th. Finally, Weiss Ratings assumed coverage on Vogenx in a research report on Monday, November 9th. They issued a “sell (e-)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.50.

About Vogenx

Vogenx Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc. is based in RALEIGH, NC.